Synsei is a highly focused team working with some of the top fetal cardiologists and obstetricians in the world to address critical fetal health needs. Though the electrocardiogram (ECG) is a standard part of cardiac care for children and adults, at present, there is no beat-to-beat ECG system available to diagnose arrhythmias in fetuses in the routine inpatient or outpatient clinical setting. This significantly limits the ability of fetal cardiologists to monitor and treat high-risk fetuses with fetal arrhythmias and other critical problems including abnormalities in cardiac conduction associated with congenital heart disease or myocardial ischemia in those at risk for cardiac dysfunction or heart failure. When anti-arrhythmic medications are administered to a mother to treat the fetus, toxicity for the mother is assessed by ECG but there is no way to monitor toxicity in the fetus without the ability to measure changes in ECG waveforms and intervals.
The Synsei fetal ECG (fECG) solves these problems with a non-invasive device that distinguishes and monitors the full beat-to-beat ECG of mothers and multiple fetuses, through electrodes on the mother’s chest and abdomen. It provides an essential tool for the fetal cardiologist for evaluating, monitoring and treating potentially fatal cardiac arrhythmias, fetuses at risk for cardiac dysfunction or heart failure, and those with congential heart disease.
The Synsei fECG is a compact device that allows in-patient or remote monitoring for high risk patients, beginning as early as 20 weeks. During labor and delivery, it provides a device that is more accurate, more comfortable and less expensive than widely used Doppler ultrasound based devices, and also provides data for the 30% of patients in the US who are too obese to monitor by such devices.